

Amendments to the Claims:

Please amend the claims to read as follows:

1. (Original) A method of induction of amyloid plaques, the method comprising the steps of:
 - a) immobilizing a quantity of a selected sulfated glycosaminoglycan (SGAG) or a GAG-related macromolecule on a selected medium;
 - b) adding to the immobilized SGAG on the medium a quantity of dissolved low fibrillar A β 1-40 (LFA β).
2. (Original) The method of Claim 1, wherein the LFA β is added in a A β :SGAG weight/weight (w/w) ratio range of between 1:0.01 to 1:20.
3. (Original) The method of Claim 2, wherein the LFA β is added in a A β :SGAG w/w ratio range of between 1:0.1 to 1:10.
4. (Original) The method of Claim 3, wherein the LFA β is added in a A β :SGAG w/w ratio range of between 1:0.5 to 1:2.
5. (Original) The method of Claim 4, wherein the LFA β is added in a A β :SGAG w/w ratio of about 1:1.
6. (Original) The method of Claim 1, wherein the selected medium is either a slide, a film or a titer well plate.
7. (Original) The method of Claim 1, wherein the SGAG is selected from the group of SGAGs consisting of heparin, heparan sulfate, keratan sulfate, dermatan sulfate, chondroitin-4-sulfate and chondroitin-6-sulfate, and the GAG-related macromolecule is dextran sulfate.
8. (Currently Amended) The method of Claim 6, wherein the titer well plate is an 18 - 96 well Teflon PTFE fluoropolymer partitioned slide.
9. (Original) The method of Claim 8, wherein the LFA β is added to the immobilized SGAG by a bubbling technique.
10. (Currently Amended) A method of induction of amyloid plaques, the method comprising the steps of:
 - a) immobilizing a quantity of a sulfated glycosaminoglycan (SGAG) or a GAG-related macromolecule on a Teflon PTFE fluoropolymer partitioned slide well, the SGAG

selected from the group of SGAGs consisting of heparin, heparan sulfate, keratan sulfate, dermatan sulfate, chondroitin-4-sulfate and chondroitin-6-sulfate, and the GAG-related macromolecule is dextran sulfate;

- b) adding to the immobilized SGAG on the slide well a quantity of dissolved low fibrillar A β 1-40 (LFA β), wherein the LFA β is added in a A β :SGAG w/w ratio range of between 1:0.5 to 1:2 by bubbling the LFA β into the slide well.

11-32. (Withdrawn)